NASDAQ · Biotechnology · USD

LB Pharmaceuticals Inc (LBRX) Stock Analysis

LB Pharmaceuticals Inc (LBRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LBRX

$49.34

+$1.82 (+3.83%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LBRX with… →

LBRX Key Statistics

As of Sep 4, 2026

Trading

Open: $47.47
Previous Close: $47.52
Day's Range: 47.47–49.91
52-Week Range: 13.36–50.16
Volume: 206.00K

Valuation

Market Cap: $1.59B
P/E Ratio: unprofitable
EPS (ttm): −5.29

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$25.21M
Profit margin: 0.00%
Shares Outstanding: 32.26M
1-Year Return: +185.20%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 337.66K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LBRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

Year	Return
2026 (partial year)	+121.65%
2025 (partial year)	+28.67%

As of September 4, 2026.

LBRX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$25.21M	—
2024	$0.00	−$63.10M	—
2023	$0.00	−$6.28M	—
2022	$0.00	−$14.35M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$30.40M	−$25.21M	—
2024	$0.00	—	−$64.83M	−$63.10M	—
2023	$0.00	—	−$11.38M	−$6.28M	—
2022	$0.00	—	−$2.81M	−$14.35M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LBRX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	LBRX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values LB Pharmaceuticals Inc (LBRX) at $1.59B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 49.

The 52-week range on file runs from $13.36 to $50.16. LBRX last closed at $49.34 on September 4, 2026. That is +$1.82 (+3.83%) against the previous close. The latest close sits 269.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $25.21M. Profit margin runs at 0%. Trailing earnings per share are −5.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is +185.20%. Annualized volatility over the trailing 1 year is 63.01%.

Growth & Income

The record shows no dividend for LBRX.

So far in 2026 the price is +121.65%.

Peer Comparison

LB Pharmaceuticals Inc (LBRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
LB Pharmaceuticals Inc	LBRX	$1.59B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. LB Pharmaceuticals Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Visit website →